Economic evaluations of personalized medicine: existing challenges and current developments



Shabaruddin, Fatiha H, Fleeman, Nigel D ORCID: 0000-0002-4637-9779 and Payne, Katherine
(2015) Economic evaluations of personalized medicine: existing challenges and current developments. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 8. pp. 115-126.

[thumbnail of Economic evaluations of personalized medicine: existing challenges and current developments.pdf] Text
Economic evaluations of personalized medicine: existing challenges and current developments.pdf - Published version

Download (289kB)

Abstract

Personalized medicine, with the aim of safely, effectively, and cost-effectively targeting treatment to a prespecified patient population, has always been a long-time goal within health care. It is often argued that personalizing treatment will inevitably improve clinical outcomes for patients and help achieve more effective use of health care resources. Demand is increasing for demonstrable evidence of clinical and cost-effectiveness to support the use of personalized medicine in health care. This paper begins with an overview of the existing challenges in conducting economic evaluations of genetics- and genomics-targeted technologies, as an example of personalized medicine. Our paper illustrates the complexity of the challenges faced by these technologies by highlighting the variations in the issues faced by diagnostic tests for somatic variations, generally referring to genetic variation in a tumor, and germline variations, generally referring to inherited genetic variation in enzymes involved in drug metabolic pathways. These tests are typically aimed at stratifying patient populations into subgroups on the basis of clinical effectiveness (response) or safety (avoidance of adverse events). The paper summarizes the data requirements for economic evaluations of genetics and genomics-based technologies while outlining that the main challenges relating to data requirements revolve around the availability and quality of existing data. We conclude by discussing current developments aimed to address the challenges of assessing the cost-effectiveness of genetics and genomics-based technologies, which revolve around two central issues that are interlinked: the need to adapt available evaluation methods and identifying who is responsible for generating evidence for these technologies.

Item Type: Article
Uncontrolled Keywords: pharmacogenetics, pharmacogenomics, cost-effectiveness, economic evaluation, somatic variations, germline variations
Depositing User: Symplectic Admin
Date Deposited: 03 May 2017 10:42
Last Modified: 19 Jan 2023 07:05
DOI: 10.2147/PGPM.S35063
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3007180